Much research has been done on how ICER evaluations influence payer decision making. However, less is known about the effect of ICER assessments on pricing and market access since making such associations is limited by having to rely on publicly available data. In this article, Xcenda explores the impact of ICER evaluations on drug pricing and coverage using two real-life examples that received considerable media attention. Read the full story here.
(Source: Annie Yan, PharmD; Xcenda; 11/3/20)